Promatix Biosciences presents new target discovery platform for cancer therapies
Biotechnology firm Promatix Biosciences presented its new proteomics-driven platform designed to expand cancer targets and improve safety and efficacy for next-generation antibody-drug conjugates (ADCs) at the AACR 2026 meeting.
Promatix Biosciences, a UK-based biotechnology company, presented new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating its proprietary integrated proteomics-driven discovery platform. The platform identifies novel, tumor-selective antigen pairs, significantly expanding the target space for next-generation antibody-drug conjugates (ADCs) and addressing a key limitation in cancer therapy development: the scarcity of truly tumor-selective targets.
Traditionally, ADC development has been constrained by a limited number of targets that are specific to cancer cells. Promatix's platform combines TxPro proteomics profiling with CipherPro computational modeling to identify complementary antigen pairs. By employing logic-gating, where binding requires interaction with both antigens (an "AND-gate" mechanism), the company aims to enhance selectivity for tumor cells, improve efficacy, and reduce toxicity.
"Target selection is the critical bottleneck in ADC development for achieving meaningful improvements in efficacy and safety," said Michael Hunter, CEO and Co-Founder of Promatix. "Our integrated platform is designed to overcome this limitation through a systematic, data-driven approach. It greatly expands the universe of viable tumor-selective targets beyond what conventional monospecific approaches can achieve."
The company's lead program involves a bispecific candidate targeting EGFR and EphA2, intended for the treatment of colorectal cancer. Experimental validation of this candidate confirms the platform's predictive power in translating logic-gated bispecific modeling into biologically actionable targets, paving the way for more effective and safer cancer treatments.